Adaptive Biotechnologies Corporation
ADPTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. With a market capitalization of $3.88B, it sits in mid-cap territory. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Market Cap
$3.88B
Beta
2.10
P/E (TTM)
—
P/E (Fwd)
-131.76
EPS (TTM)
$-0.40
EPS (Fwd)
$-0.18
ROE
-38.8%
ROA
-4.1%
Cash
$344.3M
Total Debt
$410.5M
Free CF
$19.0M
52W Change
95.5%
Annual Financials
Cash vs Debt
Where ADPT stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, ADPT finished 48.89% above its 150-day moving average ($17.57) and 51.13% above its 200-day moving average ($17.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADPT overbought or oversold?
At the August 27, 2026 close, ADPT's RSI(14) was 70.9, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $344.3M in cash, though total debt stands at $410.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $19.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -38.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $154.3M (2021) to $277.0M (2025), reflecting a 79% increase over the period.
A beta of 2.10 means ADPT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing ADPT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.